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Abstract
Background: Traditional prognostic indicators of breast cancer, i.e. lymph node diffusion, tumor size, grading and
estrogen receptor expression, are inadequate predictors of metastatic relapse. Thus, additional prognostic parameters
appear urgently needed. Individual oncogenic determinants have largely failed in this endeavour. Only a few individual
tumor growth drivers, e.g. mutated p53, Her-2, E-cadherin, Trops, did reach some prognostic/predictive power in
clinical settings. As multiple factors are required to drive solid tumor progression, clusters of such determinants were
expected to become stronger indicators of tumor aggressiveness and malignant progression than individual
parameters. To identify such prognostic clusters, we went on to coordinately analyse molecular and histopathological
determinants of tumor progression of post-menopausal breast cancers in the framework of a multi-institutional case
series/case-control study.
Methods: A multi-institutional series of 217 breast cancer cases was analyzed. Twenty six cases (12 %) showed disease
relapse during follow-up. Relapsed cases were matched with a set of control patients by tumor diameter, pathological
stage, tumor histotype, age, hormone receptors and grading. Histopathological and molecular determinants of tumor
development and aggressiveness were then analyzed in relapsed versus non-relapsed cases. Stepwise analyses and
model structure fitness assessments were carried out to identify clusters of molecular alterations with differential
impact on metastatic relapse.
Results: p53, Bcl-2 and cathepsin D were shown to be coordinately associated with unique levels of relative risk
for disease relapse. As many Ras downstream targets, among them matrix metalloproteases, are synergistically
upregulated by mutated p53, whole-exon sequence analyses were performed for TP53, Ki-RAS and Ha-RAS, and
findings were correlated with clinical phenotypes. Notably, TP53 insertion/deletion mutations were only detected
in relapsed cases. Correspondingly, Ha-RAS missense oncogenic mutations were only found in a subgroup of
relapsing tumors.
Conclusions: We have identified clusters of specific molecular alterations that greatly improve prognostic
assessment with respect to singularly-analysed indicators. The combined analysis of these multiple tumor-relapse
risk factors promises to become a powerful approach to identify patients subgroups with unfavourable disease
outcome.
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Background
Breast cancer (BC) is the most frequent malignancy in
women with 800 cases out of 100,000 people, four-times
as many as the second most frequent one, i.e. colorectal
cancer [1]. Histopathology classification of BC according
to tumor grade, stage, histotype, lymph node invasion
and hormonal receptor status [2] is broadly used to
draw correlations with survival. However, this classifi-
cation performs poorly in predicting differential bio-
logical aggressiveness of tumors with identical grade
and stage. As an example, patients with the best prog-
nosis, i.e. bearing small size tumors, expressing estro-
gen receptors and without lymph node invasion,
experience early tumor relapse in 10-20 % of the
cases [3, 4]. Cases that relapse do not detectably differ
from those that do not, as far as conventional prog-
nostic parameters are concerned.
Determinants of tumor biological history are expected
to add to traditional prognostic classification algorithms
[5, 6]. Individual oncogenic determinants, e.g. p53, Her-
2, E-cadherin, BRCA-1, Trops, have indeed been shown
to add to prognostic and predictive procedures [5, 7–
11]. However, they largely failed to outperform trad-
itional prognostic indicators.
Tumor development depends on the accumulation of
several specific genetic and epi-genetic changes [12–14].
Thus, the analysis of individual oncogenic factors is un-
likely to suffice in defining the biological nature and ag-
gressiveness of a tumor [15]. Major control pathways or
clusters of drivers of cell growth, apoptosis or invasion
are, on the other hand, expected to associate with tumor
aggressiveness and overall malignancy much more
strongly than individual factors. In this work we went on
to test this model. Histopathology and oncogenically-
activated determinants of tumor progression of BC were
analyzed in the framework of a case-control study. The
results obtained were evaluated by means of statistical
analyses able to detect significant interactions of bio-
logical determinants connected with tumor relapse. This
showed that correlated p53, Bcl-2 and cathepsin D spe-
cifically associate with unprecedented high levels of rela-
tive risk for local invasion and metastatic relapse. As
matrix metalloproteases, which play a key role in local
invasion and distant cancer spreading, were shown to be
a transactivation target for mutant p53, in cooperation
with oncogenic Ras, exon sequence analysis was per-
formed for TP53 and RAS genes, and findings were co-
ordinately analyzed with the immunohistochemistry
(IHC) data and clinical phenotypes.
Methods
Breast cancer case series
A multi-institutional case series of BC patients was col-
lected from the National Cancer Institute of Naples, to-
gether with the University of Udine, the district hospital
of Venice and Rovigo, Italy. Two hundred and seventeen
BC patients were analyzed (Table 1). Clinical data (age,
family history, clinical stage, disease follow-up) and con-
ventional prognostic indicators (size, pathological stage,
local invasion, margin width, lymph-node invasion,
histological type, necrosis, inflammatory infiltration,
Table 1 Patient case series
Age (mean ± SD) 64.7 ± 10.9
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hormonal receptor status) were recorded [16, 17]
(Table 1). Cancer grade was determined as described
[18] (Table 1; Additional file 1: Table S1 and Additional
file 2: Table S2). Twenty six cases (12 %) showed disease
relapse during follow-up (Additional file 1: Table S1).
Relapsed cases were matched with a set of control pa-
tients by tumor diameter, pathological stage, tumor his-
totype, age, hormone receptors and grading (Additional
file 1: Table S1), and analyzed for expression of tumor
progression determinants by immuno-histochemistry
(IHC) and DNA sequencing, as indicated. To identify
patterns of aggregation of molecular alterations associ-
ated to different classes of BC prognosis, stepwise
grouping procedures were performed for model struc-
ture fitness assessment, as described.
Histopathology
Tissue micro-arrays (TMA) of tumor samples were as-
sembled as described [19, 20]. Briefly, whole-tumor sec-
tions of formalin-fixed paraffin-embedded (FFPE) BC
samples were stained with hematoxylin-eosin, and used
for guiding selection of tumor-containing areas. Three
1 mm diameter cylinders were then obtained from all tu-
mors and transferred to recipient blocks. Filled blocks
were heated for 15 min at 37 °C to induce the tumor
cores to adhere to the paraffin walls. TMA sections were
analysed by IHC for the expression of markers relevant
to tumor development and aggressiveness (Figs. 1, 2 and
3, Table 1). Briefly, 5 μm sections of BC TMA were
mounted onto Vectabond-coated slides (Vector Labora-
tory). Before staining, sections were heated at 56 °C and
dewaxed in xylene/ethanol. Endogenous peroxidase was
blocked with hydrogen peroxide in methanol. Heat-
mediated ‘antigen retrieval’ was performed by treatment
in pH 6 citrate buffer in a pressure cooker or microwave
oven, as required for each specific target. After pre-
incubation with appropriate blocking agents, e.g.
species-matched normal serum, sections was incubated
with the primary antibody (Additional file 3: Table S3).
After washing, sections were challenged with fragment
antigen-binding (Fab)2 biotinylated secondary reagents,
followed by avidin-peroxidase and 3,3′-diaminobenzidine
Fig. 1 Expression of p53, Bcl-2, ERα and Her-2 in BC. Representative examples of highly expressing (left column) versus negative/low cases
(middle column) are shown. Negative controls are shown on the right. Nuclei were counterstained with Mayer’s hematoxylin (in blue). Original
magnification: ×400
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tetrachlorohydrate, activated with 0.3 % hydrogen
peroxide. Nuclei were counterstained with Mayer’s
hematoxylin. Appropriate normal mouse/rabbit second-
ary reagents or unrelated antibodies were used as nega-
tive controls. Primary antibodies directed against the
chosen targets are listed in Table 2. Immunoreactivity
for the various reagents was quantified on an average of
1000 cells in randomly chosen fields (40x objective).
Semiquantitative scores were determined by two
independent observers (M. P. and R. L.). Percent ex-
pression values of ER, PR and HER2 tended to distrib-
ute around discrete values (0, 10, 25, 50, 75 and 100 %
of tumor cells) and were categorized accordingly. Per-
centages of Ki-67 and p53 expressing cells were ana-
lyzed without discretization, but are reported here as
categorical variables for convenience (0, 1–10, 11–75,
76–100) [8]. Intensity scores varied between 0 and 3,
where 0 is no reactivity, 1 is borderline detectability, 3
Fig. 2 Expression of cathepsin D in BC Representative examples are shown. Positive/high (left column) versus negative/low (right column) cases
for expression of cathepsin D and MMP11 are indicated. Nuclei were counterstained with Mayer’s hematoxylin (in blue). a, b Tumor cases with
high cathepsin D expression both in cells and in the stroma between the tumor cells. c, d Tumor cases with low/nil cathepsin D expression in
cells, but with detectable expression in the tumor stroma. e Case with high cathepsin D expression in tumor cells, but no expression in the
stroma. f Case with no cathepsin D expression in tumor cells, but high expression in the stroma. g Case with low/nil cathepsin D expression in
both tumor cells and stroma. h Negative control for staining. Original magnification: ×400
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is the maximum observed intensity and 2 corresponds
to an intermediate intensity. A combined score was ob-
tained by multiplying percentages of positive cells by
intensity. Scores were then categorized for statistical
evaluation [21].
DNA extraction
FFPE BC sections were processed as described [22, 23].
This procedure provided with relatively crude DNA
preparations, which, however, could be efficiently used
as a template in ≤150 bp-long polymerase chain reaction
(PCR) amplifications [24]. Briefly, four 5 μm tumor sec-
tions were deparaffinized by two extractions with either
xylene or Histoclear (Carlo Erba), followed by two ex-
tractions with ethanol. Samples were then digested for
3 h at 50 °C with proteinase K (PK) 2 mg/ml, Tween 20,
Tris-Cl 50 mM, EDTA 1 mM, pH 8.5, then overnight at
50 °C after PK replenishing. Samples were then incu-
bated at 95 °C for 15 min to inactivate PK, centrifuged
at top speed for 15 min at 4 °C, transferred to a fresh
tube and stored at − 20 °C. DNA yields were quantified
by ethidium bromide fluorescence in solution [25]. On
average 30 μg DNA/sample were obtained. Size distribu-
tion of the extracted DNA [26] was profiled by ethidium
bromide/agarose gel electrophoresis for sample quality
assessment.
PCR amplification
After thawing, DNA samples prepared as above were in-
cubated at 95 °C for 25 min (this step was critical for
successful amplification). One μl of this crude extract
was added to the amplification mix. Primers were de-
signed using Primer3 [27, 28] (Additional file 4: Table
S4). TP53 exons (from 2 to 11) were separately amplified
Fig. 3 Expression of MMP11, uPA, PAI-1 in BC. Representative examples of highly expressing (left column) versus negative/low cases (middle
column) are shown. Negative controls are shown on the right. Nuclei were counterstained with Mayer’s hematoxylin (in blue)
Table 2 Antibodies utilized for immuno-histochemical
detection
Target protein Antibody Type Provider
Bax p-19a polyclonal Santa Cruz
Bcl-2 100/D5 polyclonal Novocastra/YLEM
Cathepsin D cat-D polyclonal DAKO
Cyclin D1 DCS6 monoclonal Novocastra/YLEM
Cyclin E 13A3 monoclonal Novocastra/YLEM
ERα MU368-UC monoclonal Biogenex
Her-2/erb-B/neu Hercep-test polyclonal DAKO
Ki-67 MIB-1 monoclonal Novocastra/YLEM
p16/INK4 p16 polyclonal Pharmingen
p27/kip1 F-8 monoclonal Santa Cruz
p53 DO7 monoclonal NeoMarkers
PAI-1 sc-6642 polyclonal Santa Cruz
PgR 1A6 polyclonal Ventana
Stromelysin/MMP11 sc-8837 polyclonal Santa Cruz
uPA sc-6830 polyclonal Santa Cruz
aantibodies were utilized as described in Methods
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using optimized primer sets; exons 4 and 5 were
amplified as two overlapping amplicons, using non-
overlapping primers, to prevent loss of mutations detec-
tion capacity in the primer-annealing region.
Reactions were performed in 30 μl total volume (15 μl
KapaBlood PCR Kit B, 0.5 μl of template pretreated
DNA, 20 pmol primer forward, 20 pmol primer reverse).
For multiplex reactions, TP53 was amplified under the
following conditions: 4 cycles (denaturation at 94 °C for
30 s; annealing at 68 °C for 45 s {-1 °C/cycle}; extension
at 72 °C for 30 s), 14 cycles (denaturation at 94 °C for
30 s; annealing at 63 °C for 30 s; extension at 72 °C for
30s); 30 cycles (denaturation at 94 °C for 30 s; annealing
at 60 °C for 30 s; extension at 72 °C for 30s) and a final
extension at 72 °C for 10 min. PCR products were ana-
lyzed by agarose gel electrophoresis.
Sequence analysis of TP53, Ha-RAS and Ki-RAS in human
tumors
In both Ha-RAS (c-Ha-RAS1) and Ki-RAS (c-Ki-RAS2)
activating oncogenic mutations are found at hotspots in
exon 1 and 2, at codons 12, 13 (exon 1) or 61 (exon 2).
Care was taken to differentially amplify the regions of
interest of functional genes versus non-expressed pseu-
dogenes, i.e. c-Ha-RAS2 and c-Ki-RAS1. Benchmark
PCR amplification of Ha- and Ki-RAS exons 1 and 2 was
performed using genomic DNA and cDNA from the
T24 cell line, which carries a mutated, oncogenic form
of Ha-RAS with a transversion at codon 12 (from GGC
to GTC). When using cDNA templates, PCR primers
were designed that reside in exonic regions, for simul-
taneous amplification of both exon 1 and 2 of Ha-and
Ki-RAS. Joint amplification of exon 1 and 2 from gen-
omic DNA was only performed for the Ha-RAS gene
(the intervening intron is only 267 bp long in the Ha-
RAS gene; it is more than 12,500 bp long in the Ki-RAS
gene). Additional primers were designed that included
intronic regions and were therefore specific for amplifica-
tion of functional genes from genomic DNA. Amplified
fragments were sequenced on both strands. Insertions or
deletions (indels) of the TP53 gene (Additional file 5:
Table S5) were shown to carry the highest prognostic
weight [29]; such mutations were identified and matched
against those listed in the IARC database [29].
Statistical analysis
The independent impacts of individual risk factors on
prognosis is commonly evaluated in the framework of
uni-or multivariate models [8, 19, 30, 31]. Univariate
analyses were performed with GraphPad Prism 6.0
(GraphPad Software Inc., La Jolla, Ca) and XLStat 2009
(Addinsoft, Paris, France). Multivariate analyses and data
modeling were performed using MetaboAnalyst 2.0 [32–
34] and SIMCA-P+ 11 (Umetrics, Umea, Sweden) [35]
software. However, uni-or multivariate analyses do not
effectively quantify interaction effects on the final out-
come. To explore such interactions, a priori specified
hypotheses have been used in the past as trial models,
but at the risk of introducing analytical bias. To over-
come these limitations, patterns of aggregation of mo-
lecular parameters affecting prognosis were modeled
here through logistic regression and partial least squares
discriminant analysis (PLS-DA). PLS-DA clustering was
performed using relapse as a dichotomic variable. PLS-
DA model validation was performed as previously de-
scribed [36]. Briefly, to define the optimal number of
PCs, “7-fold cross-validation” (CV) was applied [37].
Using CV, the predictive power of the model was veri-
fied through R2 (goodness of fit) and Q2 (goodness of
prediction). A model with Q2 > 0.5 was considered good,
Q2 > 0.9 excellent [38]. The performance of PLS-DA
models was further validated by a permutation test (200
times). To help interpreting results from PLS-DA, we
utilized variable importance in the projection (VIP)
scores. This allowed to evaluate the parameter influence
on the model and to identify the best descriptors of
relapsing versus non-relapsing BC. VIP scores are
weighted sums of squares of the PLS loading weights,
which take into account the amount of explained Y-
variation for each dimension [33]. VIP values were cu-
mulatively calculated from all extracted PLS compo-
nents, usign a threshold of 0.8 [39]. As some variables
may exert effects on the whole population (global), while
others can be relevant in specific subgroups only (local),
procedures were utilized to identify homogeneous sub-
groups with respect to corresponding parameters sub-
classes [40–42]. Spearman’s correlation analysis was
performed using MetaboAnalyst 2.0 software [32–34]
and GraphPad Prism.
Results
Immunohistochemistry and correlation analysis
Histopathology and molecular biology determinations
were performed as indicated [43, 44] (Figs. 1, 2 and 3;
Additional file 1: Table S1 and Additional file 2: Table
S2). Negative/positive correlations between histopatho-
logical and experimental parameters were assessed by
Spearman’s correlation analysis (Additional file 3: Table
S3). Strongest positive correlations with metastastic re-
lapse were found for grading (rho = 0.454, p = 0.005),
local relapse (rho = 0.892, p < 0.001), p53_n (rho = 0.309,
p = 0.067) and uPA in the extracellular matrix (rho =
0.387, p = 0.02). Highest negative correlations (Add-
itional file 3: Table S3) were observed between metastas-
tic relapse and intracellular uPA (percent cytoplasmic:
rho = -0.369, p = 0.027; expression intensity: rho = -0.435,
p = 0.008). Of interest, p53 expression (% positive cells
and intensity) was found to be associated with secreted
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cathepsin D (rho = 0.477, p = 0.003) and was negatively
correlated with Bcl-2 (rho = -0.385, p = 0.02). p53 expres-
sion was correlated with grading (rho = 0.499, p = 0.002),
cyclin E (rho = 0.335, p = 0.046), PAI-1 in the extracellu-
lar matrix (rho = 0.444, p = 0.007), Her-2 (rho = 0.368, p
= 0.027) and p16 (rho = 0.514, p = 0.001) expression, first
suggesting key interactions and potential synergy with
other key drivers of tumor malignancy.
Prognostic parameters analysis
Internal benchmarks for additional risk determination pro-
cedures were first assessed. Biochemically-determined
negativity for estrogen receptors was associated with re-
lapse. Estrogen receptor negativity, by semi-quantitative
IHC determination, was associated with twice as high re-
lapse hazard ratio (HR) (HR = 2.0; 95 % C.I. = 0.6–7.4). An
increased mitotic index (Ki-67 expression) was associated
with increased risk of developing adverse events (HR = 2.6;
95 % C.I. = 0.6–11.2), consistent with previous studies [31].
Correlated analysis of the analyzed tumor determi-
nants revealed marked increase in HR for p53, cathepsin
D and Bcl-2 (Figs. 1, 2). Positivity for p53 nuclear ex-
pression was found to associate with an eleven-fold in-
crease in relapse risk (HR = 11; 95 % C.I. = 2.5–51.8).
Unprecedented increase in risk was found for cathepsin
D expression (HR = 20; 95 % C.I. = 2.3–184.3). Notably,
expression profiles of p53 and cathepsin D remained sig-
nificantly different between cases and controls when
subgrouping patients by lymph node status, supporting
an independent prognostic value of these parameters.
Lymph node diffusion correlated with local cancer re-
lapse (rho = 0.405, p = 0.014), but did not with distant
metastatic relapse, raising the issue that determinant of
local invasion may differ from those required for meta-
static diffusion. Hence, we assessed the impact of p53
and cathepsin D in lymph node-negative patients. Re-
markably, tumor co-expression of p53 and cathepsin D
in this patient subgroup remained associated to a
sixteen-fold higher risk of experiencing relapse (HR = 16;
95 % C.I. = 1.5–171.2). Trends for association of positive
lymph nodes and tumor size were found: 50 and 78 % of
lymph-node-positive women were positive for p53 and
cathepsin D, respectively; 63 and 74 % of women with
tumors bigger than 2 cm were positive for p53 and ca-
thepsin D, respectively.
Remarkably, the expression of Bcl-2 was associated
with a markedly better prognosis, and a nine-fold reduc-
tion of risk (HR = 9.2; 95 % C.I. = 1–87.8). Bcl-2 expres-
sion was previously found to correlate with a
differentiated cancer phenotype, i.e. with lower grading
and lack of p53 [45]. Consistent, Bcl-2 expression was
found to correlate with that of ERα and PgR, and was
anti-correlated with cancer grading and with the expres-
sion of p53, Cyclin E and Her-2 (Table S3).
Correspondingly, Bcl-2 expression was shown to have a
beneficial influence on prognosis [46, 47], whereas loss
of Bcl-2 was found in 70 % of the aggressive triple-
negative BC, and was significantly associated with high
proliferation, tumor progression, increased risk of death
and recurrence [48]. Still, the magnitude of Bcl-2 prog-
nostic impact observed here in metastatic versus non-
metastatic BC had not been previously revealed [49],
supporting a critical value of correlated evaluation of
malignancy determinants (Bcl-2, p53, cathepsin D) for
effective use in prognostic assessment.
To verify the strength of this unsupervised analysis,
and to further build on it, we performed a supervised
PLS-DA [50]. Datasets of pathological/experimental pa-
rameters were grouped using a dichotomic classification
(metastatic relapse versus no relapse). This model was
found to have strong goodness of fit (cumulative R2Y =
0.828) and prediction power (cumulative Q2 = 0.548)
(Figs. 4, 5 and 6). PLS-DA-identified determinants clus-
ters yielded a clear-cut discrimination between meta-
static versus non metastatic tumours (Figs. 4, 5a). A
PLS-DA weight plot was generated in order to identify
the major discriminants between the groups analyzed
(Fig. 4). Next, VIP scores were computed for each par-
ameter. Twenty descriptors, i.e. local relapse, grading,
HER-2 (membrane intensity), lymph node status, p53,
p16, Bcl-2, Cyclin E, PgR, together with stromal cathep-
sin D, PAI-1, uPA and MMP-11 were found to markedly
contribute to the classification model (VIP score ≥ 0.8)
(Fig. 5b) [39]. Permutation tests were carried out in
order to validate the PLS-DA model [38, 50]. The ori-
ginal model was found to have higher R2 and Q2 values
than the permuted models, and negative Q2 values were
obtained for all two permuted groups tested (Fig. 5c).
DNA extraction
DNA was extracted from sections of FFPE BC (Add-
itional file 1: Table S1A). Ethidium bromide gel electro-
phoresis (Fig. 7) and amplification of RAS and TP53
exons benchmarked DNA as viable for downstream ana-
lyses. RAS and TP53 sequences were determined on
cases and control DNA (Additional file 1: Table S1), as
described (Figs. 7 and 8).
TP53 mutations
Case and control FFPE tumor samples, were systematic-
ally analyzed for insertions, deletions and stop codons in
the coding region of the TP53 gene by PCR and sequen-
cing of PCR amplification products (Figs. 7 and 8; Add-
itional file 5: Table S5). Structural alterations of the
TP53 gene are listed in Additional file 5: Table S5. Three
indels were identified, and one stop codon, all of which
led to truncation of the corresponding p53 proteins. Re-
markably, all truncated p53 (8.7 % of the BC cases) were
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identified in relapsing cancers, three out of four cases
being grade 3, i.e. those with the most malignant pheno-
type. These findings support models were severely dam-
aged p53 is a strong risk factor for tumor progression in
defined subgroups of BC [7, 8, 10, 31]. Notably, though,
only one of these cases was a triple-negative tumor, a
tumor phenotype traditionally associated with tumor ag-
gressiveness [8], suggesting that the present molecular
characterization may lead to novel subgrouping strat-
egies of BC for risk determination. However, larger case
series are needed to validate this approach.
RAS mutations
Case and control BC samples, were analyzed for muta-
tions at codons 12, 13, 14 and 61 of the Ha-RAS and Ki-
RAS genes by PCR amplification and sequencing of the
first and second exon. Three cases showed a mutation at
codon 12 of Ha-RAS, from GGC to GTC (Gly→Val); one
case showed an additional mutation at codon 14 from
GTG to ATG (Val→Met), with an overall prevalence of
tumors bearing RAS mutations of 6.4 % (Additional file 1:
Table S1). Of note, all mutations occurred in the meta-
static and locally invasive/relapsing cases. This suggested
relevance of mutated Ha-RAS in a small, distinct subset of
metastatic BC. Mutations of both Ha-RAS and TP53 were
identified in the same cancer, suggesting a possible coop-
erativity in cell transformation [51].
Discussion
Traditional prognostic indicators of BC, i.e. lymph node
diffusion, tumor size, grading and estrogen receptor ex-
pression, are inadequate predictors of metastatic relapse.
Therefore, identification of additional parameters versus
traditional prognostic indicators is urgently needed. Sev-
eral genes (oncogenes, tumor suppressor genes, tran-
scription factors, signaling molecules, adhesion proteins,
proteases) play a driving role in tumor progression [52].
Individual oncogenic determinants, e.g. p53, Her-2, E-
cadherin, Trops, have been shown to possess prognostic/
predictive power [7–11, 20, 53]. However, they did not
outperform traditional prognostic indicators. Tumor
progression is a multistep process [13, 54–58], which
correlates with multiple, successive molecular modifica-
tions [13, 14]. Hence, clusters of tumor-driving traits are
expected to be associated with tumor aggressiveness and
overall malignancy, much more strongly than individual
Fig. 4 PLS-DA weight plot. Variables utilized for discrimination between the relapsing and non-relapsing groups are reported. Variables that better
correlate with metastatic tumors, map in the top right quadrant; variables that correlate more with non metastatic tumors, map in the lower left
quadrant. Inset: local relapse (magnified scale)
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factors. In this work, we tested such a model in BC.
Histopathological and molecular determinants of tumor
progression of post-menopausal BC were analyzed, to
assess impact on metastatic relapse. Aggregation of can-
cer determinants was expolored by modeling through
discriminant analysis, logistic regression, partial least
squares and partition trees. This identified upregulation
of p53 and cathepsin D, together with downregulation of
Bcl-2, as associated with a major increase in risk of dis-
ease relapse.
p53 is a tumor suppressor gene which is frequently
mutated in cancer cells [59], and was identified as an
indicator of both prognosis [8, 60–62] and response to
therapy [7]. A cooperation of p53 with other drivers of
tumor progression, e.g. Her-2 [8, 63] and Trop-1/Ep-
CAM [10, 64] was previously shown, thus lending sup-
port our model of interaction between distinct prognos-
tic determinants.
Bcl-2 inhibits cellular apoptosis [65]. Hower, Bcl-2 ex-
pression has a stronger impact as indicator of retained
cancer differentiation, and of better disease outcome
[45]. Indeed, loss of Bcl-2 was shown to have negative
prognostic impact [46, 47, 49]. Bcl-2 expression was lost
in 70 % of the most aggressive triple-negative BC cases,
Fig. 5 PLS-DA score plot and VIP scores. a PLS-DA score plot showing the clustering of tumor samples with (green perimeter) or without (red
perimeter) metastatic relapse. Complete separation between the green versus red clusters was achieved. Clustering thresholds were applied as
indicated in Methods. b Variables able to discriminate between metastatic and non metastatic tumors are presented, as ordered by VIP score. VIP
scores≥ 0.8 (above the red line) identified key variables for predicting Y responses (relapse)
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i.e. those lacking ERα, PgR and Her-2, and was signifi-
cantly associated with high proliferation, tumor progres-
sion and increased risk of death and recurrence [48].
Supporting these findings, we found that Bcl-2 expres-
sion negatively correlated with cancer grading and with
the expression of p53, cyclin E and Her-2. On the other
hand, Bcl-2 expression was found to correlate with that
of ERα and PgR, i.e. with differentiated cancer
phenotypes.
Proteases, e.g. cathepsin D, uPA, MMP-11, are se-
creted by transformed or stromal cells of BC, and impact
on tumor invasion and mestastasis [66–76]. uPA is mod-
ulated by the plasminogen activator inhibitor-1 (PAI-1),
and combined assessment of uPA and PAI-1 was shown
to be of value for prognostic determination [77, 78], in-
dicating an impact of overall proteolytic balance on
tumor progression. As indicated above for loss of Bcl-2,
triple-negative BC were frequently associated with over-
expression of cathepsin-D, and with aggressive disease
course through lymph node invasion and high cancer
cell proliferation/Ki-67 index [79].
As for the additional determinants we analyzed, cyclins
D and E regulate the cell cycle [80], and increased levels
are associated with worse prognosis and increased re-
lapse rates in BC patients [81]. p27/kip1 and p16/INK4
are inhibitors of cyclin-dependent kinases and can pre-
vent progression through the cell cycle [55], but can also
be determinants of malignancy. High levels of the p27/
kip1 cyclin inhibitor have been associated with worse
prognosis and higher relapse rate in BC [82, 83]. On the
other hand, deletion of p16/INK4 can be selected for in
BC [84]. Consistent with an interactive predictive value,
the levels of Cyclin E and of the p27 cyclin inhibitor
were shown to have a higher impact when combined
[82]. The mitotic index (Ki-67) is a measure of the per-
centage of tumor cells in active division and is a relevant
prognostic indicator in BC [31]. Her-2 is a transmem-
brane tyrosine kinase receptor that regulates the growth
of tumor cells [85]. The levels of expression of Her-2
have been shown to be independent indicators of worse
prognosis, with respect to tumor relapse and overall sur-
vival in BC patients [86].
To identify interaction effects of different variables on
disease outcome, expression profiles of tumor progres-
sion drivers were assessed, and results were evaluated by
means of statistical analyses designed to detect
Fig. 6 PLS-DA cross-validation and performance. a Bar plot showing the performance measures (R2Ycum and Q2cum) using different numbers of
components. b R2X: portion of the variation of X explained by specified principal component; R2X (cum) Cumulative explained portion of X set
variation; Eigenvalue: number of variables (K) times R2X; R2Y: portion of the Y set variation modeled by the principal component; R2Y (cum):
cumulative modeled variation of Y set; Q2: overall cross-validated R2 for the specific principal component; Limit: threshold cross-validation for the
specific principal component; Q2 (cum): cumulative Q2 up to the specified component, is a model predictive power according to cross validation.
Unlike R2X (cum), Q2 (cum) is not additive. c Permutation tests for: metastatic (left) and non metastatic tumors (right). Permutation tests were
performed by comparing R2and Q2 of the original model with R2 and Q2 of Y-class-permutated models. The correlation coefficients of original
and permuted data are reported on the X axis; 200 random permutations were carried out. The values of R2 and Q2 are reported on the Y axis.
The green triangles and blue squares in the upper right (ρ = 1) correspond to the values of R2 (green triangles) and Q2 (blue squares) of the
original data. The low values of intercepts show that the model has high statistical significance (no over-fitting)
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significant prognostic interaction. To preempt the need
for a priori specified hypotheses, patterns of aggregation
of molecular parameters affecting prognosis were mod-
eled through logistic regression and PLS-DA, using re-
lapse as a dichotomic variable. PLS-DA score plot
clustering of tumor samples with or without disease re-
lapse, obtained separation between the two clusters.
Major discriminant parameters were shown to be, HER-
2, p53, p16, Cyclin E, PgR, together with stromal cathep-
sin D, PAI-1, uPA and MMP-11 were found to mark-
edly contribute to the classification model; these
efficiently clustered with local relapse, lymph node dif-
fusion, tumor staging and grading. Among prognostic
factors, p53 and cathepsin D stood up as major deter-
minants of cancer relapse. Bcl-2 expression was shown
to provide with unprecedented protective power ver-
sus tumor recurrence, candidating the combined as-
sessment of these IHC parameters for use in clinical
settings. Of interest, our case-control study included
only one triple negative BC, indicating that a triple
negative status was not a confounding variable in our
study, and that p53, cathepsin D and Bcl-2 are effi-
cient aggressiveness determinants in BC across cur-
rently categorized cancer subgroups.
Specific mutations of oncogenes and tumor suppressor
genes play key roles in tumor progression. TP53 is fre-
quently inactivated in several human tumors [87–89]
and TP53 mutations help classifying and selecting pa-
tient subgroups with different biological features [8, 90],
particularly in BC [8, 10, 31]. Mutations in different re-
gions of TP53 were shown to be heterogenous in nature
[91] and clinical outcome, indels having the highest im-
pact [92]. Consistent, sequencing of the TP53 gene re-
vealed a subgroup of BC where truncating mutations,
such as indels and stop codons, were in all cases associ-
ated with cancer relapse.
The RAS genes code for small G proteins that play a
critical role in signal transduction pathways downstream
Fig. 7 Oncogene sequence analysis. (top) Genomic DNA was extracted from BC and electrophoresed in agarose/ethidium bromide. Sample
numbers are on top of each lane; mw: molecular weight markers. (mid) Exon-intron structure of the TP53 gene. (bottom) PCR amplification of the
TP53 exons. EX: exon number; multiplex: simultaneous amplification of all exons with optimized primers and amplification procedure; mw:
molecular weight markers
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of growth-factor receptors. RAS mutations can affect
prognosis [93–95]. Moreover, Ras downstream target
genes are synergistically upregulated by mutated p53
and Ha-Ras, among them, matrix metalloproteases,
which play a key role in local invasion and distant dis-
semination [96]. Hence, hot-spot sequence analysis was
performed for Ha-and Ki-RAS, and findings were corre-
lated with the IHC data and clinical phenotypes. The
constitutive activation of the Ras proteins by point mu-
tations, concentrated in hotspots at codons 12, 13, 61,
is among the most frequently observed oncogene acti-
vation in human malignancies (75 % of adenocarcin-
omas of the pancreas, 40 % of adenomas and
carcinomas of the colon and rectum, 25 % of carcin-
omas of the lung) and have been linked to worse prog-
nosis [97]. However, although mutations in Ha-RAS
and of Ki-RAS are often found in animal models of BC
[98], their mutation frequency in human BC was shown
to vary widely across studies. c-Ki-RAS mutations were
shown to occur in 1 out of 8 BC by Yanez et al. [99].
Ha-RAS mutations were detected by Spandidos et al.
[100], but not by Biunno et al. [101]. An overall low fre-
quency of Ha-RAS mutations was found in most subse-
quent studies [97, 102–106]. Our findings support an
incidence of mutated Ha-RAS in ≈ 5 % of BC cases. No
mutations were detected in Ki-RAS. Remakably, all
RAS mutations were identified in relapsed cases, sug-
gesting impact of mutated Ha-RAS in a distinct sub-
set of malignant BC [97, 104–106]. This finding
warrants testing in a prospective clinical trial with ad-
equate size and predictive power for relapsed cases
subgroup dissection.
Conclusions
Taken together, our findings support a model of high
BC aggressiveness as associated to high levels of p53 [8,
10] and cathepsin D [79], together with a downregula-
tion of Bcl-2 [48]. An interaction between tumor-
relapse risk factors may thus have a marked impact on
prognosis, paving the way for using cluster molecular





Fig. 8 TP53 coding regions sequencing. a Block scheme of the p53 functional domains, protein sequence residues numbers are shown; Pro rich:
proline-rich; tetra: oligomerization domain; reg: negative regulator of p53 function. b Prevalence of TP53 mutations in the different regions of the
gene (from IARC TP53 Database, Release 17); (top) frequency of somatic mutations in BC; (bottom) frequency of germline, hereditary mutations in
Li-Fraumeni syndrome. c Representative example of a DNA sequence chromatogram, containing a mutated sequence (see also Additional file 5:
Table S5); the mutation site is boxed; the corresponding amino acid sequence is indicated
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